Jean-Michel Foidart

7PUBLICATIONS
17CO-AUTHORS
Toxicology (incl. clinical toxicology)Epidemiological modellingBioavailability and ecotoxicologyFood properties (incl. characteristics and health benefits)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 27, 2025
Critical Considerations in the Interpretation of Bone Turnover Marker Data in Hormonal Contraceptive Users. Comment on Tassi et al. Hormonal Contraception and Bone Metabolism: Emerging Evidence from a Systematic Review and Meta-Analysis of Studies on Post-Pubertal and Reproductive-Age Women. Pharmaceuticals 2025, 18, 61.

Jonathan Douxfils, Jean-Michel Foidart

|Jun 28, 2023
Estetrol Is Safe and Well Tolerated during Treatment of Hospitalized Men and Women with Moderate COVID-19 in a Randomized, Double-Blind Study.

Jean Michel Foidart, Krzysztof Simon, Wulf H Utian

|Jun 10, 2023
Comparison of Estetrol Exposure between Women and Mice to Model Preclinical Experiments and Anticipate Human Treatment.

Anne Gallez, Gwenaël Nys, Vincent Wuidar

|Nov 18, 2022
Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women.

J Douxfils, U Gaspard, M Taziaux

|Aug 12, 2022
Bleeding Patterns of Oral Contraceptives with a Cyclic Dosing Regimen: An Overview.

David F Archer, Diana Mansour, Jean-Michel Foidart

|Jul 21, 2022
A novel estetrol-containing combined oral contraceptive: European expert panel review.

Kristina Gemzell-Danielsson, Angelo Cagnacci, Nathalie Chabbert-Buffet

Pageof 2

Frequent Collaborators

5 joint publications

Jonathan Douxfils

2 joint publications

Kristina Gemzell-Danielsson

2 joint publications

Nathalie Chabbert-Buffet

1 joint publications

Angelo Cagnacci